Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Vacuolar protein sorting 35 is a regulator of tau phosphorylation and neuropathology

Aug. 5, 2019

AC Immune initiates phase Ib/IIa study of ACI-35.030 vaccine for the treatment of AD

Aug. 5, 2019

T20K demonstrates favorable safety and tolerability in first-in-human study

Aug. 2, 2019

Rewind Therapeutics to discover drugs for myelin-related neurological diseases

Aug. 2, 2019

AZD-0530 shows no statistically significant effect on cerebral metabolic decline in AD

Aug. 2, 2019

Positive interim data presented for AAV gene therapy in children with CLN6 Batten disease

Aug. 2, 2019

DSMB recommends continuation of phase II study of ANAVEX 2-73 for Rett syndrome

Aug. 1, 2019

Roche synthesizes gamma-secretase inhibitors

Aug. 1, 2019

Sage Therapeutics identifies new GABA-A receptor modulators

Aug. 1, 2019

Eisai reports death in phase I study of E-2082

July 31, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...